This ad will auto close in 10 seconds

Ranbaxy says Europe bars imports from antibiotic injectables unit

The European Union has banned imports from a Ranbaxy Laboratories Ltd factory unit that makes injectable antibotics after the unit failed an inspection, the latest in a series of quality-related setbacks for the Indian drugmaker.

US denies Ranbaxy's bid to block launch of rival generics

A US court has denied a request by drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc`s heartburn pill Nexium and Roche`s antiviral, a court filing showed.

Ranbaxy sues USFDA for revoking approval to sell 2 drugs

Ranbaxy Laboratories has sued USFDA over revoking an approval to sell generic versions of two drugs -- digestive disorder medicine Nexium and anti-viral Valcyte-- in the US market.

Ranbaxy to pay $40 million to settle Texas litigation

The payments will be made in tranches through August 2015.

Ranbaxy's recalls 29,790 packs of anti-allergy drug in US

Ranbaxy started recalling 29,790 packs of an allergy-relief medicine in the United States after finding defects in the packaging.

Unease grows among US doctors over Indian drug quality

India supplies about 40 percent of generic and over-the-counter drugs used in the United States, making it the second-biggest supplier after Canada.

Ranbaxy falls around 16% after FDA bans products

Shares in Ranbaxy Laboratories Ltd, majority owned by Japan`s Daiichi Sankyo Co Ltd, slumped around 16 percent in early trade after the US Food and Drug Administration banned more products from the Indian drugmaker.

FDA raises more concerns about Ranbaxy's India plants

The company, India`s biggest drugmaker by sales, said the FDA had now filed "certain observations" about its Toansa pharmaceutical ingredients plant in Punjab.

Wockhardt hit by new export ban from UK regulator

Britain's drug authorities have revoked their approval for one of Wockhardt Ltd's key plants - a fresh regulatory rebuke that sent shares in the Indian drugmaker tumbling and underscores the long road it faces in restoring its reputation.

Ranbaxy under scanner of other regulators after USFDA alert

The regulators said action will be taken after assessing the FDA's reply.

Ranbaxy seeks to assuage shareholders' worries

Drug major Ranbaxy Laboratories Friday sought to assuage concerns of shareholders in the wake of company's stock price taking a hard knock after the US Food and Drug Administration banned the import of drugs from its Mohali plant.

Certain consent decree terms to apply to Mohali unit: Ranbaxy

"The FDA also ordered that the Mohali facility be subject to certain terms of the consent decree of permanent injunction entered against Ranbaxy in January 2012," according to United States Food and Drug Administration website.

US import alert on Ranbaxy; Mohali unit part of consent decree

"The firm will remain on the import alert until the company complies with U.S. Drug manufacturing requirements, known as current good manufacturing practices (CGMP)," USFDA said in a statement.

Ranbaxy falls about 30% after FDA import alert

A third Ranbaxy Laboratories plant in India has been sanctioned with an import alert ban from the US Food and Drug Administration, triggering the worst single day fall in its stock on Monday and a brokerage downgrade.

Ranbaxy Lab dips nearly 7% on bourses

Shares of Ranbaxy Laboratories Monday dipped by nearly 7 percent on reports that the company's manufacturing facility at Mohali has come under the USFDA's scanner.

Health ministry backs Ranbaxy

Backing pharma major Ranbaxy, who has been accused of marketing sub-standard medicines, the health ministry Friday said there was nothing wrong with the quality of its drugs.

Ranbaxy drugs are 'safe and efficacious': SAfrican regulator

Generic drugs distributed in South Africa by Indian pharmaceutical giant Ranbaxy are "safe" and "efficacious", the country's regulator body said Wednesday, days after the beleaguered drug maker paid a fine of USD 500 million in the US for selling adulterated drugs there.

PIL in Supreme Court for action against Ranbaxy

An advocate Wednesday approached the Supreme Court with a PIL seeking cancellation of the license granted to Ranbaxy Laboratories Ltd and for initiating probe against the pharma major for allegedly manufacturing and selling adulterated drugs.

Ranbaxy gets approval to market Ran-Rosuvastatin drug in Canada

Indian generic drug maker Ranbaxy Laboratories Ltd. said Saturday that its subsidiary in Canada got an approval from Health Canada to manufacture and market Ran-Rosuvastatin tablets, a cholesterol-lowering medication, to the Canadian healthcare system.

Ranbaxy posts loss of Rs 2,982 crore for Oct-Dec

Ranbaxy Laboratories Ltd, India's top drugmaker by sales, reported a quarterly loss of Rs 29.83 billion, mainly due to a provision related to a probe by the US Justice Department.